Is XGN or FLGT more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Fulgent Genetics -26.05% -4.93% -4.50%

Is XGN or GMRS more profitable?

GMR Solutions has a net margin of 0.00% compared to Exagen's net margin of -26.61%. GMR Solutions' return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% GMR Solutions N/A N/A N/A

Does the media prefer XGN or GMRS?

In the previous week, GMR Solutions had 2 more articles in the media than Exagen. MarketBeat recorded 4 mentions for GMR Solutions and 2 mentions for Exagen. Exagen's average media sentiment score of 1.28 beat GMR Solutions' score of 0.27 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GMR Solutions 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, SBC or XGN?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SBC Medical Group $173.61M 3.10 $50.99M $0.47 11.13 Exagen $66.57M 3.06 -$19.95M -$0.81 N/A

Is SBC or XGN more profitable?

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets SBC Medical Group 27.99% 18.47% 13.10% Exagen -26.61% -104.46% -28.93%

Does the media prefer SBC or XGN?

In the previous week, SBC Medical Group had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for SBC Medical Group and 2 mentions for Exagen. Exagen's average media sentiment score of 1.28 beat SBC Medical Group's score of 0.84 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SBC Medical Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, XGN or VMD?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 3.06 -$19.95M -$0.81 N/A Viemed Healthcare $270.28M 1.37 $14.93M $0.36 26.92

Is XGN or VMD more profitable?

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Viemed Healthcare 4.81% 10.16% 7.22%

Does the media favor XGN or VMD?

In the previous week, Exagen and Exagen both had 2 articles in the media. Exagen's average media sentiment score of 1.28 beat Viemed Healthcare's score of 0.61 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viemed Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exagen (XGN) Competitors

$8.56 +0.14 (+1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$8.55 -0.01 (-0.12%)

As of 04:10 PM Eastern

Compare

XGN vs. FLGT, GMRS, SBC, SRTA, and VMD

Should you buy Exagen stock or one of its competitors? Exagen's main competitors and comparable companies include Fulgent Genetics (FLGT), GMR Solutions (GMRS), SBC Medical Group (SBC), Strata Critical Medical (SRTA), and Viemed Healthcare (VMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Exagen compare to Fulgent Genetics?

Exagen (NASDAQ:XGN) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Exagen has higher earnings, but lower revenue than Fulgent Genetics. Exagen is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A
Fulgent Genetics	$322.67M	1.79	-$60.51M	-$2.82	N/A

Exagen currently has a consensus price target of $9.75, suggesting a potential upside of 15.80%. Fulgent Genetics has a consensus price target of $27.50, suggesting a potential upside of 30.89%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Exagen had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.82 beat Exagen's score of 1.28 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Positive
Fulgent Genetics	Very Positive

Exagen has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

75.3% of Exagen shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Summary

Exagen beats Fulgent Genetics on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to GMR Solutions?

Exagen (NASDAQ:XGN) and GMR Solutions (NYSE:GMRS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

GMR Solutions has lower revenue, but higher earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than GMR Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A
GMR Solutions	N/A	N/A	N/A	-$1.56	N/A

In the previous week, GMR Solutions had 2 more articles in the media than Exagen. MarketBeat recorded 4 mentions for GMR Solutions and 2 mentions for Exagen. Exagen's average media sentiment score of 1.28 beat GMR Solutions' score of 0.27 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GMR Solutions	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GMR Solutions has a net margin of 0.00% compared to Exagen's net margin of -26.61%. GMR Solutions' return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
GMR Solutions	N/A	N/A	N/A

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Exagen currently has a consensus price target of $9.75, indicating a potential upside of 15.80%. GMR Solutions has a consensus price target of $18.78, indicating a potential upside of 75.99%. Given GMR Solutions' higher possible upside, analysts plainly believe GMR Solutions is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Exagen beats GMR Solutions on 7 of the 12 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

SBC Medical Group (NASDAQ:SBC) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

SBC Medical Group presently has a consensus target price of $8.50, suggesting a potential upside of 62.52%. Exagen has a consensus target price of $9.75, suggesting a potential upside of 15.80%. Given SBC Medical Group's higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SBC Medical Group	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, SBC Medical Group had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for SBC Medical Group and 2 mentions for Exagen. Exagen's average media sentiment score of 1.28 beat SBC Medical Group's score of 0.84 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SBC Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.8% of SBC Medical Group shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 81.7% of SBC Medical Group shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SBC Medical Group	$173.61M	3.10	$50.99M	$0.47	11.13
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SBC Medical Group	27.99%	18.47%	13.10%
Exagen	-26.61%	-104.46%	-28.93%

SBC Medical Group has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Exagen has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

Summary

SBC Medical Group beats Exagen on 10 of the 16 factors compared between the two stocks.

How does Exagen compare to Strata Critical Medical?

Exagen (NASDAQ:XGN) and Strata Critical Medical (NASDAQ:SRTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

75.3% of Exagen shares are held by institutional investors. Comparatively, 47.4% of Strata Critical Medical shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 15.5% of Strata Critical Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Exagen had 1 more articles in the media than Strata Critical Medical. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Strata Critical Medical. Strata Critical Medical's average media sentiment score of 1.76 beat Exagen's score of 1.28 indicating that Strata Critical Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Positive
Strata Critical Medical	Very Positive

Exagen has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Strata Critical Medical has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

Exagen presently has a consensus target price of $9.75, suggesting a potential upside of 15.80%. Strata Critical Medical has a consensus target price of $8.00, suggesting a potential upside of 86.92%. Given Strata Critical Medical's higher possible upside, analysts plainly believe Strata Critical Medical is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

Strata Critical Medical has a net margin of 15.71% compared to Exagen's net margin of -26.61%. Strata Critical Medical's return on equity of -2.97% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Strata Critical Medical	15.71%	-2.97%	-2.54%

Strata Critical Medical has higher revenue and earnings than Exagen. Strata Critical Medical is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A
Strata Critical Medical	$197.14M	1.92	$41.35M	-$0.04	N/A

Summary

Strata Critical Medical beats Exagen on 10 of the 15 factors compared between the two stocks.

How does Exagen compare to Viemed Healthcare?

Exagen (NASDAQ:XGN) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A
Viemed Healthcare	$270.28M	1.37	$14.93M	$0.36	26.92

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Viemed Healthcare	4.81%	10.16%	7.22%

75.3% of Exagen shares are held by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 20.6% of Viemed Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Exagen currently has a consensus price target of $9.75, suggesting a potential upside of 15.80%. Viemed Healthcare has a consensus price target of $14.00, suggesting a potential upside of 44.48%. Given Viemed Healthcare's higher probable upside, analysts plainly believe Viemed Healthcare is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Exagen has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Exagen and Exagen both had 2 articles in the media. Exagen's average media sentiment score of 1.28 beat Viemed Healthcare's score of 0.61 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viemed Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viemed Healthcare beats Exagen on 8 of the 15 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$207.41M	$10.45B	$7.44B	$12.94B
Dividend Yield	N/A	2.61%	2.52%	19.59%
P/E Ratio	-10.57	34.47	275.00	25.39
Price / Sales	3.12	4.67	569.10	75.48
Price / Cash	N/A	115.88	76.68	52.75
Price / Book	11.12	5.21	10.32	6.02
Net Income	-$19.95M	$315.68M	$3.49B	$380.68M
7 Day Performance	4.77%	0.63%	-2.50%	-3.01%
1 Month Performance	14.29%	-3.58%	-6.83%	-5.61%
1 Year Performance	-28.19%	10.45%	1.85%	-5.24%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	2.988 of 5 stars	$8.56 +1.7%	$9.75 +13.9%	-27.0%	$207.41M	$66.57M	N/A	220	News Coverage Analyst Forecast
FLGT Fulgent Genetics	3.2094 of 5 stars	$21.59 +3.7%	$27.50 +27.4%	-6.2%	$594.46M	$322.67M	N/A	1,315
GMRS GMR Solutions	3.2271 of 5 stars	$10.52 -0.2%	$18.78 +78.5%	N/A	$568.31M	$5.88B	N/A	34,000	Short Interest Increase
SBC SBC Medical Group	4.0853 of 5 stars	$5.40 +1.0%	$8.50 +57.6%	+25.7%	$554.24M	$175.17M	11.47	863
SRTA Strata Critical Medical	2.5082 of 5 stars	$4.56 +1.9%	$8.00 +75.6%	N/A	$402.98M	$197.14M	N/A	601	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. FLGT, GMRS, SBC, SRTA, and VMD

How does Exagen compare to Fulgent Genetics?

Summary

How does Exagen compare to GMR Solutions?

Summary

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to Strata Critical Medical?

Summary

How does Exagen compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. FLGT, GMRS, SBC, SRTA, and VMD

How does Exagen compare to Fulgent Genetics?

Which has stronger valuation and earnings, XGN or FLGT?

Do analysts prefer XGN or FLGT?

Does the media refer more to XGN or FLGT?

Which has more volatility and risk, XGN or FLGT?

Do insiders and institutionals believe in XGN or FLGT?

Is XGN or FLGT more profitable?

Summary

How does Exagen compare to GMR Solutions?

Which has better earnings & valuation, XGN or GMRS?

Does the media prefer XGN or GMRS?

Is XGN or GMRS more profitable?

Do institutionals and insiders have more ownership in XGN or GMRS?

Do analysts recommend XGN or GMRS?

Summary

How does Exagen compare to SBC Medical Group?

Do analysts recommend SBC or XGN?

Does the media prefer SBC or XGN?

Do insiders and institutionals hold more shares of SBC or XGN?

Which has stronger earnings and valuation, SBC or XGN?

Is SBC or XGN more profitable?

Which has more risk & volatility, SBC or XGN?

Summary

How does Exagen compare to Strata Critical Medical?

Do institutionals & insiders hold more shares of XGN or SRTA?

Does the media refer more to XGN or SRTA?

Which has more volatility & risk, XGN or SRTA?

Do analysts recommend XGN or SRTA?

Is XGN or SRTA more profitable?

Which has preferable earnings & valuation, XGN or SRTA?

Summary

How does Exagen compare to Viemed Healthcare?

Which has preferable valuation & earnings, XGN or VMD?

Is XGN or VMD more profitable?

Do institutionals & insiders hold more shares of XGN or VMD?

Do analysts prefer XGN or VMD?

Which has more risk & volatility, XGN or VMD?

Does the media favor XGN or VMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools